Literature DB >> 19449021

Accumulation of TDP-43 and alpha-actin in an amyotrophic lateral sclerosis patient with the K17I ANG mutation.

Danielle Seilhean1, Cécile Cazeneuve, Valérie Thuriès, Odile Russaouen, Stéphanie Millecamps, François Salachas, Vincent Meininger, Eric Leguern, Charles Duyckaerts.   

Abstract

A K17I mutation in the ANG gene encoding angiogenin has been identified in a case that we previously published as ALS with neuronal intranuclear protein inclusions (Seilhean et al. in Acta Neuropathol 108:81-87, 2004). These inclusions were immunoreactive for smooth muscle alpha-actin but not for angiogenin. Moreover, they were not labeled by anti-TDP-43 antibodies, while numerous cytoplasmic inclusions immunoreactive for ubiquitin, p62 and TDP-43 were detected in both oligodendrocytes and neurons in various regions of the central nervous system. In addition, expression of smooth muscle alpha-actin was increased in the liver where severe steatosis was observed. This is the first neuropathological description of a case with an ANG mutation. Angiogenin is known to interact with actin. Like other proteins involved in ALS pathogenesis, such as senataxin, TDP-43 and FUS/TLS, it plays a role in RNA maturation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449021     DOI: 10.1007/s00401-009-0545-9

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  35 in total

1.  TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation.

Authors:  Maria Martinez-Lage; Laura Molina-Porcel; Dana Falcone; Leo McCluskey; Virginia M-Y Lee; Vivianna M Van Deerlin; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-08       Impact factor: 17.088

Review 2.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

Review 3.  New insights into the role of angiogenin in actin polymerization.

Authors:  Mikhail G Pyatibratov; Alla S Kostyukova
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

4.  TDP-43 causes differential pathology in neuronal versus glial cells in the mouse brain.

Authors:  Sen Yan; Chuan-En Wang; Wenjie Wei; Marta A Gaertig; Liangxue Lai; Shihua Li; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2013-12-30       Impact factor: 6.150

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Fronto-temporal lobar degeneration: neuropathology in 60 cases.

Authors:  Danielle Seilhean; Isabelle Le Ber; Marie Sarazin; Lucette Lacomblez; Stéphanie Millecamps; François Salachas; Pierre-François Pradat; Nadine Le Forestier; Eric LeGuern; Bruno Dubois; Vincent Meininger; Alexis Brice; Jean-Jacques Hauw; Charles Duyckaerts
Journal:  J Neural Transm (Vienna)       Date:  2011-05-04       Impact factor: 3.575

Review 7.  TDP43 and RNA instability in amyotrophic lateral sclerosis.

Authors:  Kaitlin Weskamp; Sami J Barmada
Journal:  Brain Res       Date:  2018-01-31       Impact factor: 3.252

Review 8.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

Review 9.  Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases.

Authors:  Takakuni Maki; Kazuhide Hayakawa; Loc-Duyen D Pham; Changhong Xing; Eng H Lo; Ken Arai
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-05-01       Impact factor: 4.388

10.  Shortened TDP43 isoforms upregulated by neuronal hyperactivity drive TDP43 pathology in ALS.

Authors:  Kaitlin Weskamp; Elizabeth M Tank; Roberto Miguez; Jonathon P McBride; Nicolás B Gómez; Matthew White; Ziqiang Lin; Carmen Moreno Gonzalez; Andrea Serio; Jemeen Sreedharan; Sami J Barmada
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.